Novo Nordisk, a global health care company headquartered in Denmark and Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, US, announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.